Cytori Therapeutics Gets Celution System Approval In Singapore - Quick Facts

(RTTNews) - Cytori Therapeutics (CYTX) has obtained approval from the Health Sciences Authority or HSA in Singapore for the Celution System for autologous re-implantation or re-infusion of a patient's own adipose-derived regenerative cells or ADRCs. The Celution System helps in accessing a patient's own ADRCs at the point-of-care for various injuries and conditions.

"We anticipate seeing a relevant impact on sales in 2014 as a result of the approval in Singapore, combined with recent approvals and registrations in Australia, New Zealand and in Japan," said Seijiro Shirahama, President of Asia-Pacific for Cytori.

Cytori would continue to pursue new regulatory approvals in large markets and strategic countries in Asia as well as expand existing claims for the Celution System in over 40 countries where it already has approval. Asia-Pacific has been and continues to be a key region for Cytori, supported by a growing number of regulatory approvals and patents issued.